MedTrace Logo

Imaging Study of [89Zr]DFO-YS5 for Cancer Detection

NCT07664397 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-06-24

No results posted yet for this study

Summary

This is a single-center, pilot, PET-imaging study of the novel radiotracer 89Zirconium-89 DFO conjugated to the YS5 monoclonal antibody (\[89Zr\]DFO-YS5) in participants with nerve sheath tumor, bladder cancer, or advanced solid tumor neoplasms.

Conditions

  • Bladder Cancer
  • Nerve Sheath Tumor
  • Nerve Sheath Tumors
  • Solid Tumor Malignancies
  • Solid Tumor Cancer
  • Solid Tumor Neoplasms
  • Advanced Solid Tumor
  • Bladder Neoplasm
  • Nerve Sheath Neoplasms
  • Nerve Sheath Tumor, Nos
  • Solid Tumor, Adult
  • Solid Carcinoma

Interventions

DRUG

[89Zr]DFO-YS5

Given intravenously (IV)

PROCEDURE

Positron Emission Tomography (PET)-Magnetic resonance imaging (MRI)

Participants may receive a whole-body PET-MRI or a whole body PET-CT

PROCEDURE

Positron Emission Tomography (PET)-Computerized tomography (CT)

Participants may receive a whole-body PET-CT or a whole-body PET-MRI

Sponsors & Collaborators

  • Kyntra Bio

    collaborator INDUSTRY

  • Fortis Therapeutics, Inc.

    collaborator INDUSTRY

  • Robert Flavell, MD, PhD

    lead OTHER

Principal Investigators

  • Robert Flavell, MD · University of California, San Francisco

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-01
Primary Completion
2029-09-30
Completion
2029-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07664397 on ClinicalTrials.gov